Omolara Otaigbe, MD
Family Medicine · Hattiesburg, MSNPI 1932164456
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AbbVie at 54.1% of the total. Reporting peaked in 2022 at $9,594 and has fallen 96.1% since, to $377 in 2025. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $110.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Cardinal Health 110 LLC$6K
- Global Blood Therapeutics, Inc.$357
- Amarin Pharma, Inc.$257
- Gilead$225
- Novo Nordisk$186
- plus $952 from 16 others
What the payments were for
- Consulting fees$5,95034%
- Speaking & faculty fees$8,16147%
- Food & beverage$3,15618%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $9,356 |
| Cardinal Health 110 LLC | 8 | $5,950 |
| Global Blood Therapeutics, Inc. | 19 | $357 |
| Amarin Pharma, Inc. | 15 | $257 |
| Gilead | 12 | $225 |
| Novo Nordisk | 12 | $186 |
| AstraZeneca | 12 | $165 |
| GSK | 7 | $125 |
| Otsuka America Pharmaceutical, Inc. | 5 | $120 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Exact Sciences | 4 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Galderma Laboratories, L.p. | 4 | $67 |
| Pfizer | 3 | $55 |
| Lilly USA, LLC | 3 | $44 |
| Astellas Pharma US Inc | 2 | $43 |
| Insulet Corporation | 1 | $21 |
| Abbott | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$129
How this compares
$17,284 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ShingrixVaricella-Zoster Ge/As01b/Pf | 25,789 | $5,058,913 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 16,237 | $4,468,721 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 4,710 | $1,335,933 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 5,124 | $304,354 |
| TwinrixHepatitis A And B Vaccine/Pf | 1,677 | $215,408 |
| OzempicSemaglutide | 125 | $176,805 |
| MounjaroTirzepatide | 82 | $106,206 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 1,527 | $89,744 |
| JardianceEmpagliflozin | 95 | $62,753 |
| FarxigaDapagliflozin Propanediol | 81 | $61,720 |
| EliquisApixaban | 152 | $47,861 |
| M-M-R Ii VaccineMeasles,mumps,rubella Vacc/Pf | 205 | $20,874 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,190 |
| Gardasil 9Hpv Vaccine 9-Valent/Pf | 54 | $14,116 |
| CreonLipase/Protease/Amylase | 15 | $13,860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix, Arexvy, Twinrix, Trelegy Ellipta, Havrix | $125 | $9,765,25643,800 claims |
| PfizerAbrysvo, Eliquis | $55 | $1,383,7944,862 claims |
| Novo NordiskOzempic | $186 | $176,805125 claims |
| Lilly USA, LLCMounjaro | $44 | $106,20682 claims |
| AstraZenecaFarxiga | $165 | $61,72081 claims |
| AbbVieCreon, Synthroid | $9,356 | $16,44839 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $7,80513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Hattiesburg
- Deborah CopelandHattiesburg$13K
- J DumasHattiesburg$12K
- Anny EvansHattiesburg$10K
- Melanie HallHattiesburg$10K
- Stephen LambertHattiesburg$9K
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.